Home
Issues
Deals
Ledger
Research
About
Lilly buys AtaiBeckley
·
$3.8bn
Otsuka buys Transcend
·
$1.2bn
AbbVie buys Gilgamesh
·
$1.2bn
atai buys Beckley Psytech
·
terms undisclosed
AbbVie takes an option on Gilgamesh
·
$2bn
Lilly buys AtaiBeckley
·
$3.8bn
Otsuka buys Transcend
·
$1.2bn
AbbVie buys Gilgamesh
·
$1.2bn
atai buys Beckley Psytech
·
terms undisclosed
AbbVie takes an option on Gilgamesh
·
$2bn
Lilly buys AtaiBeckley
·
$3.8bn
Otsuka buys Transcend
·
$1.2bn
AbbVie buys Gilgamesh
·
$1.2bn
atai buys Beckley Psytech
·
terms undisclosed
AbbVie takes an option on Gilgamesh
·
$2bn
Next issue
Issue 16 · Tue 29 Sep
All issues
GH Research
Every issue covering GH Research.
3 issues
2026-09-15
No. 14
Five countries, one regulator.
TRIALS
DEALS
REGULATORY
DEFINIUM
LILLY
ATAIBECKLEY
COMPASS
GH
2026-06-11
European Psychedelic Medicine: H1 2026 in Review
RESEARCH
DEALS
COMPASS
ATAIBECKLEY
BECKLEY-PSYTECH
GH
2026-06-09
No. 1
Psychedelic Brief
RESEARCH
ACCESS
GH
COMPASS